NASDAQ
Madrigal Pharmaceuticals, Inc. (MDGL)
♥ 587 Thanks from members
Madrigal Pharmaceuticals demonstrates robust commercial momentum with Rezdiffra, surpassing 50,000 active MASH patients and driving 71% Q2 revenue growth, though widening operating losses and high valuation expectations prompt short-term volatility and close monitoring of upcoming pipeline catalysts.